Clinical trials
Phase 2 Giant Cell Arteritis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
19 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2008 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2025 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 9 |
| Recruiting | 4 |
| Terminated | 3 |
| Unknown status | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Insel Gruppe AG, University Hospital Bern | 2 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Cambridge University Hospitals NHS Foundation Trust | 1 |
| Centocor, Inc. | 1 |
| Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts | 1 |
| Centre Hospitalier Universitaire Dijon | 1 |
| Janssen Research & Development, LLC | 1 |
| Kiniksa Pharmaceuticals, Ltd. | 1 |
| Matthew J Koster | 1 |
| NYU Langone Health | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Giant Cell Arteritis | 19 |
| Takayasu Arteritis | 4 |
| Vasculitis | 4 |
| Granulomatosis with Polyangiitis | 2 |
| Polyarteritis Nodosa | 2 |
| Rheumatic Diseases | 2 |
| Arteritis | 1 |
| Arthritis, Juvenile | 1 |
| Arthritis, Psoriatic | 1 |
| Arthritis, Rheumatoid | 1 |
Trials
Showing 1 to 19 of 19. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.